Skip to main content
Figure 2 | Orphanet Journal of Rare Diseases

Figure 2

From: In vitro and in vivotherapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model

Figure 2

Cell cycle analysis of ovarian cancer cells after chemotherapeutic compound application (A) and SMARCA4/BRG-1 protein expression in human ovarian cancer cells (B). Cell cycle analysis (A) was performed by flow cytometry in SCCOHT-1GFP, NIH:OVCAR-3GFP, SK-OV-3GFP and BIN-67 cells after treatment with 1 Ī¼M cisplatin, or 1 Ī¼M carboplatin, or 2 nM epothilone B for 48 h, respectively. Western blot analysis (B) of BRG-1 protein was performed in steady state of two ovarian carcinoma cell lines (NIH:OVCAR-3 and SK-OV-3) as compared to SCCOHT-derived cells (SCCOHT-1 and BIN-67). The absence of BRG-1 in human alveolar adenocarcinoma A549 cells was used as a control and expression of Ī²-actin served as a loading control.

Back to article page